We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Mitokyne Inc. (developing drugs that improve mitochondrial function) raised $45mm in Series A funding from Astellas Pharma Inc., MPM Capital, and Longwood Founders Fund, which each add a board member. Concurrent with the financing, the company and Astellas penned a deal in which Mitokyne agreed to lead the research and discovery activities, while Astellas handles all clinical development and commercialization. The drug candidates will be aimed at mitochondria-related diseases such as genetic, metabolic, and neurodegenerative conditions and aging. In addition to getting a license to any drugs, Astellas also has the exclusive right to acquire Mitokyne outright during certain periods of their five-year alliance. Money for the acquisition alone could reach $500mm, which includes Astellas’ investment in the Series A.
Deal Industry
Pharmaceuticals
Biotechnology
Drug Discovery Tools
Deal Status
Final
Deal Type
Financing
Venture Financing
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?